The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
AvaALL: Open-label randomized phase IIIb trial evaluating the efficacy and safety of standard of care with or without continuous bevacizumab (BV) treatment beyond disease progression in patients (pts) with advanced nonsquamous non-small cell lung cancer (NSCLC) after first-line (1L) treatment with BV plus platinum-doublet chemotherapy (CT).
Cesare Gridelli
Consultant or Advisory Role - Roche
Honoraria - Roche
Jaafar Bennouna
Consultant or Advisory Role - Amgen; Boehringer Ingelheim; Roche
Honoraria - Amgen; Boehringer Ingelheim; Roche
Javier De Castro
No relevant relationships to disclose
Anne-Marie C. Dingemans
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Frank Griesinger
Consultant or Advisory Role - Roche
Honoraria - Roche
Francesco Grossi
Consultant or Advisory Role - Roche
Honoraria - Roche
Nick Thatcher
Consultant or Advisory Role - Roche
Honoraria - Roche
Expert Testimony - Roche
Other Remuneration - Roche
Yuichiro Ohe
Employment or Leadership Position - Chugai Pharma (I)
Honoraria - Chugai Pharma
Pablo Diego Perez-Moreno
Employment or Leadership Position - Roche
Corey J. Langer
Consultant or Advisory Role - Roche/Genentech
Research Funding - Roche/Genentech